Igamad: Side Effects & Dosing

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Concise Prescribing Info

Contents

Human anti-D Ig

Indications/Uses

Rh(D) -ve persons after incompatible transfusions of Rh(D) +ve blood or other products containing RBC. Prevention of Rh(D) immunisation in Rh(D) -ve women during pregnancy/delivery of Rh(D) +ve baby, abortion/threatened abortion, ectopic pregnancy or hydatidiform mole, & transplacental haemorrhage resulting from antepartum haemorrhage, amniocentesis, chorionic biopsy or obstet manipulative procedures (eg, external version or abdominal trauma).

Click to view Igamad detailed prescribing information

Dosage/Direction for Use

Slow IM Following transfusion of Rh-incompatible blood 500-1,250 IU per 10 mL of transfused blood over a period of several days. Postpartum prophylaxis 1,000-1,500 IU given to the mother as soon as possible after delivery but not later than 72 hr postpartum. Antepartum & postpartum prophylaxis Initially 1,000-1,500 IU in the 28th wk of pregnancy, then same dose w/in 72 hr after delivery if newborn is Rh(D) +ve. After interruption of pregnancy, extrauterine pregnancy or hydatidiform mole: Before the 12th wk of pregnancy 600-750 IU. After the 12th wk of pregnancy or after amniocentesis or chorion biopsy 1,250-1,500 IU. Doses are to be given w/in 72 hr of event or intervention.

Click to view Igamad detailed prescribing information

Overdosage

View Igamad overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Igamad detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Igamad detailed prescribing information

Special Precautions

Discontinue administration immediately if symptoms of allergic or anaphylactic type reactions occur. Not to be given by IV. Not for use in Rh(D) +ve individuals. Potential for development of IgA Abs & anaphylactic reactions in lgA deficient individuals. Possibility of passing on infection. Observe patients for at least 20 min after administration. Not to be given to newborn infant.

Click to view Igamad detailed prescribing information

Use In Pregnancy & Lactation

Click to view Igamad detailed prescribing information

Adverse Reactions

Local pain & tenderness at inj site. Fever, malaise, headache, cutaneous reactions & chills.

Click to view Igamad detailed prescribing information

Drug Interactions

Impaired efficacy of live attenuated virus vaccine eg, MMR.

Click to view Igamad detailed prescribing information

Caution For Usage

For caution against possible variation of physical aspect of medicine... Click to view Igamad detailed prescribing information

Storage

View Igamad storage conditions for details to ensure optimal shelf-life.

Description

View Igamad description for details of the chemical structure and excipients (inactive components).

Action

View Igamad mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J06BB01 - anti-D (rh) immunoglobulin ; Belongs to the class of specific immunoglobulins. Used in passive immunizations.

Thai FDA Category

Presentation/Packing

Form

Igamad soln for inj 750 IU/mL

Packing/Price

2 mL x 1's

Igamad

anti-d immunoglobulins

Manufacturer:

Grifols

Distributor:

DKSH